[Vasovagal syncope in pediatric patients: a medium-term follow-up analysis]

José Francisco Díaz1, Luis Tercedor, Eduardo Moreno

  • 1Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, Spain. jfdiaz@hjrj.sas.junta-andalucia.es

Insights

Pediatric vasovagal syncope patients have a good medium-term outlook. Recurrence was lower than expected, with only prior syncope history predicting future events in children.

Area of Science:

  • Pediatric Cardiology
  • Neuroscience
  • Clinical Medicine

Background:

  • Vasovagal syncope is common in children, but its long-term evolution is poorly understood.
  • Tilt testing is a diagnostic tool for syncope of unknown origin in pediatric patients.

Purpose of the Study:

  • To evaluate the medium-term clinical outcome of children diagnosed with vasovagal syncope using tilt testing.
  • To identify predictors of syncope recurrence in pediatric patients.

Main Methods:

  • Prospective study of 51 children under 17 years old who underwent tilt testing.
  • Kaplan-Meier and Cox regression analyses were used to assess syncope-free survival and predictors.

Main Results:

  • Recurrence rate of syncope was significantly lower (19%) than estimated from history (47%).
  • History of more than one syncope before tilt testing was the only independent predictor of recurrence (p=0.04).
  • Projected 38-month recurrence was 66.2% for those with multiple prior syncopes versus 0% for those with a single episode.

Conclusions:

  • Children with vasovagal syncope have a favorable medium-term prognosis with a low recurrence rate.
  • Pre-tilt test history of syncope is a key predictor, with single-episode patients experiencing no recurrence.
  • Findings aid in recommending tilt testing and guiding therapy for pediatric vasovagal syncope.
Abstract

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...